BioMarin Fabry Drug License Leads Quiet Week in Biotech Dealmaking
U.S.-listed drugmakers favored asset licensing and bankruptcy purchases of drug candidates over large company acquisitions this week, in a quieter stretch than earlier in 2026.
U.S.-listed drugmakers favored asset licensing and bankruptcy purchases of drug candidates over large company acquisitions this week, in a quieter stretch than earlier in 2026.